ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

US FDA reviewing pretomanid for tuberculosis

by Jyllian Kemsley
March 16, 2019 | APPEARED IN VOLUME 97, ISSUE 11

 

09711-polcon3-pretomanid.jpg

The US Food and Drug Administration is evaluating a new drug application for pretomanid, a new tuberculosis drug candidate. Pretomanid would be used in combination with bedaquiline and linezolid to treat patients with multi- or extensively drug-resistant TB. Pretomanid was developed by the TB Alliance, a global nonprofit group dedicated to advancing TB drug development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment